CD8A and neoplasm: Considering that anti-PD-1 is widely used for the treatment of melanoma patients, we confirmed these observations also in B16F1 tumours, by transferring CD8+ T cells specific for gp100 (pmel-1), an endogenously expressed melanocytic lineage antigen (Extended Data Fig. 3e).